Stereotaxis' Robocath system achieves 100% clinical success in 20-patient coronary intervention study

• Stereotaxis announced successful first-in-human study results for subsidiary Robocath’s next-generation coronary intervention robot in 20 patients.
• All patients achieved clinical success, with no device-related adverse events through 30-day follow-up, including patients with complex coronary disease.
• Findings were presented at the Transcatheter Cardiovascular Therapeutics conference on November 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stereotaxis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020848PRIMZONEFULLFEED9867951) on November 02, 2026, and is solely responsible for the information contained therein.